



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/435, 14/47, C12N 5/10, 15/12, 15/62, 15/63, 15/64	A1	(11) International Publication Number: WO 00/56764 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/US00/07404 (22) International Filing Date: 20 March 2000 (20.03.00) (30) Priority Data: 60/126,149 25 March 1999 (25.03.99) US (71) Applicant: BRISTOL-MYERS SQUIBB CO. [US/US]; P.O. Box 4000, Princeton, NJ 08543 (US). (72) Inventors: YANG, Guchen; 1911 Sweetbriar Road, Morrisville, PA 19067 (US). CHEN, Xiaorong; 206 Mandon Ct., Princeton, NJ 08540 (US). DAVIS, Patricia, M.; 605 Saxony Lane, Yardley, PA 19067 (US). KIENER, Peter, A.; 2 Saddleview Lane, Doylestown, PA 18901 (US). (74) Agents: KLEIN, Christopher, A. et al.; Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: DNA MOLECULES ENCODING HUMAN CLAX PROTEINS AND THEIR SOLUBLE FUSION PROTEINS**(57) Abstract**

Isolated novel cDNA sequences encoding a human C-type lectin and three homologues are provided. They are referred to herein as "CLAX" (C-type Lectin, Activation Expressed) proteins. The invention also includes methods of using the nucleic acid sequences, polypeptides encoded by the nucleic acid sequences disclosed herein, fusion proteins having all or a portion (e.g., an extracellular region) of the CLAX proteins, antibodies specific for the novel CLAXs, ligands and inhibitors for the novel CLAXs. The genes of CLAX are specifically expressed in lymphoid tissues and activated T lymphocytes but not resting T lymphocytes. The invention concerns the utility in pharmaceutical compositions for the prevention and treatment of infectious, inflammatory and allergic diseases.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DNA MOLECULES ENCODING HUMAN CLAX PROTEINS AND THEIR SOLUBLE FUSION PROTEINS

Cross-Reference to Related Application

5 This application claims the benefit of U.S. Provisional Application No. 60/126,149 filed March 25, 1999.

Field of the Invention

 The invention is generally in the field of infection, inflammation and allergy.

10 More specifically, the present invention concerns three novel DNA molecules encoding three polypeptides, which may be useful in controlling and modulating activation and differentiation of lymphoid cells. The present invention also concerns expression vectors comprising the genes, host cells comprising the expression vectors, proteins produced by the genes, methods for producing the proteins, and methods of

15 using the genes and proteins.

Background of the Invention

 Natural killer (NK) cells are lymphocytes that participate in innate immune response against certain bacteria, parasites, and viruses. (Lanier, L.L., (1998) *Annu. Rev. Immunol.* 16:359-393). NK cells express a lectin-like receptor superfamily of

20 type II transmembrane proteins (amino terminus intracellular). Their extracellular domains have structural features of C-type lectins. (Ryan, J.C., et al., (1997) *Immunol. Rev.* 155:79-89). The superfamily consists of several families including Ly-49 (in mice and rats), NKR-P1 (in mice, rats, and humans), NKG2 (in humans and

25 rats), and CD94 (in humans). These proteins are encoded by a single genetic region called the NK gene complex (NKC) which are located on human chromosome 12, mouse chromosome 6 and rat chromosome 4. Different receptors, even within the same family, have been shown to activate or to inhibit NK cell functions. (Vely, F., et al., (1997) *J. Immunol.* 159:2075-2077). In many cases, the different activities

30 mediated by individual receptors have been linked to the different structures of these receptors in their cytoplasmic domain and in their transmembrane domain.

For example, the murine Ly-49D and Ly-49H, and the human NKG2C, which possess a positively charged residue (arginine or lysine) within their transmembrane domain, have been shown to activate NK cells by associating with DAP12 membrane adapter protein. (Smith, K.M., et al., (1998) *J. Immunol.* 161:7-10; Lanier, L.L., et al., (1998) *Immunity* 8:693-701). The DAP12 contains a negatively charged residue (aspartic acid) in its transmembrane region and an immunoreceptor tyrosine-based activating motif (ITAM) in its cytoplasmic domain. Upon cross-linking of CD94/NKG2C, tyrosine residues in ITAM of DAP12 become phosphorylated and recruit tyrosine kinases, such as ZAP-70 or Syk.

On the other hand, the murine Ly-49A that lacks charged residues in its transmembrane region and contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain has been demonstrated to inhibit NK cytotoxicity. (Nakamura, M.C., et al., (1997) *J. Exp. Med.* 185:673-684). The inhibitory activity is mediated by cytoplasmic tyrosine phosphatase, SHP-1, which is recruited by the ITIM domain of Ly-49A. The tyrosine phosphatase SHP-1 can dephosphorylate the adjacent adapter proteins and kinases, resulting in the termination of activation signals.

Genes located in NKC also encode other C-type lectins such as CD69 and the recently identified receptor AICL. (Lopez-Cabrera, M., et al., (1993) *J. Exp. Med.* 178:537-547; Hamann, J., et al., (1997) *Immunogenetics* 45:295-300). Unlike the restricted expression of other NK cell receptors, both CD69 and AICL are widely expressed on hematopoietic cells including lymphocytes, monocytes and granulocytes. They are not expressed on resting, but are rapidly induced upon activation. CD69 is known as the earliest activation marker of lymphocytes. Anti-CD69 mAb can induce activation and cytokine production of T, B and NK cells, though CD69 lacks a charged residue in its intracellular domain. (Testi, R., et al., (1994) *Immunol. Today.* 15:479-483).

Because of the diverse biological activities of members of the lectin-like receptor superfamily and their close relationship to immune cell functions, those skilled in the art are interested in identifying novel members of this family. The identification and study of novel genes and proteins may lead to a better

understanding of the mechanisms underlying immune cell functions, and will permit those skilled in the art to regulate or control immune reactions or diseases.

Summary of the invention

5 The present invention includes a novel "CLAX" protein (C-type Lectin, Activation eXpressed) shown in SEQ ID NO:2 (Figure 2A) and a nucleic acid sequence (SEQ ID NO:1) encoding said CLAX protein. Additionally encompassed within the invention are nucleic acid sequences encoding homologues to said CLAX protein (Figures 2B, 2C and 2D). The homologues are referred to herein as clone 7B
10 (nucleic acid sequence shown in SEQ ID NO:3; amino acid sequence shown in SEQ ID NO:4); clone 2I (nucleic acid sequence shown in SEQ ID NO:5; amino acid sequence shown in SEQ ID NO:6); and clone 4A (nucleic acid sequence shown in SEQ ID NO:7; amino acid sequence shown in SEQ ID NO:8). The nucleotide sequences of the isolated cDNA's are disclosed herein along with the deduced amino
15 acid sequences. The cDNA genes of the above clones have been deposited with the American Type Culture Collection and given the Accession Numbers ATCC HuCLAX-7B (clone 7B); ATCC HuCLAX-2I (clone 2I); and ATCC HuCLAX-4A (clone 4A).

 The present inventors sequenced the clones encoding the novel CLAX protein
20 homologues and determined the primary sequences of the deduced proteins. The nucleic acid and amino acid sequences of the novel CLAX protein disclosed herein were determined from the sequenced clones. The novel CLAX protein exhibits sequence identity to the known sequence of human CD69.

 The CLAX protein of the present invention can be produced by: (1) inserting
25 the cDNA of a disclosed CLAX into an appropriate expression vector; (2) transfecting the expression vector into an appropriate transfection host(s); (3) growing the transfected host(s) in appropriate culture media; and (4) purifying the protein from the culture media.

 The present invention therefore provides a purified and isolated nucleic acid
30 molecule, preferably a DNA molecule, having a sequence which codes for CLAX protein, or an oligonucleotide fragment of the nucleic acid molecule which is unique

to a CLAX protein of the present invention. In a preferred embodiment of the invention, the purified and isolated nucleic acid molecule has the sequence as shown in SEQ ID NO:1 (Figure 2A). In another preferred embodiment, the purified and isolated nucleic acid molecule has the sequence as shown in SEQ ID NO:3 (Figure 2B). In still another preferred embodiment the purified and isolated nucleic acid molecule has the sequence as shown in SEQ ID NO:5 (Figure 2C). In still another preferred embodiment of the present invention the purified and isolated nucleic acid molecule has the nucleotide sequence as shown in SEQ ID NO:7 (Figure 2D).

The invention also contemplates a double stranded nucleic acid molecule comprising a nucleic acid molecule of the invention or an oligonucleotide fragment thereof hydrogen bonded to a complementary nucleotide base sequence.

The terms "isolated and purified nucleic acid" and "substantially pure nucleic acid", e.g., substantially pure DNA, refer to a nucleic acid molecule which is one or both of the following: (1) not immediately contiguous with either one or both of the sequences, e.g., coding sequences, with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally occurring genome of the organism from which the nucleic acid is derived; or (2) which is substantially free of a nucleic acid sequence with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences. Substantially pure or isolated and purified DNA also includes a recombinant DNA which is part of a hybrid gene encoding additional CLAX sequence.

The present invention provides in one embodiment: (a) an isolated and purified nucleic acid molecule comprising a sequence encoding all or a portion of a protein having the amino acid sequence as shown in SEQ ID NO:2; (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which exhibit at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18

bases and which will hybridize to (a) or (b) under stringent conditions. In a particular embodiment, the nucleic acid sequence comprises (a) the sequence as shown in SEQ ID NO:1, (b) a nucleic acid sequence complementary to SEQ ID NO:1, and (c) sequences having at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a) or (b).

The degree of homology (percent identity) between a native and a mutant sequence may be determined, for example, by comparing the two sequences using computer programs commonly employed for this purpose. One suitable program is the GAP computer program described by Devereux et al., (1984) *Nucl. Acids Res.* 12:387. The GAP program utilizes the alignment method of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:433, as revised by Smith and Waterman (1981) *Adv. Appl. Math.* 2:482. Briefly, the GAP program defines percent identity as the number of aligned symbols (i.e., nucleotides or amino acids) which are identical, divided by the total number of symbols in the shorter of the two sequences.

As used herein the term "stringent conditions" encompasses conditions known in the art under which a nucleotide sequence will hybridize to an isolated and purified nucleic acid molecule comprising a sequence encoding a protein having the amino acid sequence as shown herein, or to (b) a nucleic acid sequence complementary to (a). In a preferred embodiment, stringent conditions comprise overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSPE (750 mM NaCl, 50 mM NaH₂PO₄ and 5 mM EDTA), 5x Denhardt's solution, 0.1% SDS and 100 µg/ml denatured, sheared salmon sperm DNA. One skilled in the art may vary conditions appropriately. Screening polynucleotides under stringent conditions may be carried out according to the method described in Nature, 313:402-404 (1985).

Polynucleotide sequences capable of hybridizing under stringent conditions with the polynucleotides of the present invention may be, for example, allelic variants of the disclosed DNA sequences, or may be derived from other sources. General techniques of nucleic acid hybridization are disclosed by Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1984); and by Haymes et al., "Nucleic Acid Hybridization: A Practical

Approach", IRL Press, Washington, D.C. (1985), which references are incorporated herein by reference.

The present invention provides in another embodiment: (a) an isolated and purified nucleic acid molecule comprising a sequence encoding all or a portion of a protein having the amino acid sequence as shown in SEQ ID NO:4 (clone 7B; Figure 2B); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which are at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention provides in another embodiment: (a) an isolated and purified nucleic acid molecule comprising a sequence encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:6 (clone 2I; Figure 2C); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which are at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention provides in another embodiment: (a) an isolated and purified nucleic acid molecule comprising a sequence encoding all or a portion of a protein having the amino acid sequence as shown in SEQ ID NO:8 (clone 4A; Figure 2D); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which are at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention also provides: (a) a purified and isolated nucleic acid molecule comprising a sequence as shown in SEQ ID NO:1 (Figure 2A); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences having at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention further provides: (a) a purified and isolated nucleic acid molecule comprising a sequence as shown in SEQ ID NO:3 (clone 7B; Figure 2B); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences having at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention further provides: (a) a purified and isolated nucleic acid molecule comprising a sequence as shown in SEQ ID NO:5 (clone 2I; Figure 2C); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences having at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention further provides: (a) a purified and isolated nucleic acid molecule comprising a sequence as shown in SEQ ID NO:7 (clone 4A; Figure 2D); (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences having at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) that is at least 18 bases and which will hybridize to (a) or (b) under stringent conditions.

The present invention additionally covers nucleic acid and amino acid molecules of the present invention having one or more structural mutations including replacement, deletion or insertion mutations. For example, a signal peptide may be deleted, or conservative amino acid substitutions may be made to generate a protein that is still biologically competent or active.

The invention further contemplates a recombinant molecule comprising a nucleic acid molecule of the present invention or an oligonucleotide fragment thereof and an expression control sequence operatively linked to the nucleic acid molecule or oligonucleotide fragment. A transformant host cell including a recombinant molecule of the invention is also provided.

In another aspect, the invention features a cell or purified preparation of cells which include a novel gene encoding a CLAX protein of the present invention, or which otherwise misexpresses a gene encoding a CLAX protein of the present

invention. The cell preparation can consist of human or non-human cells, e.g., rodent cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a CLAX transgene, e.g., a heterologous form of a CLAX gene, e.g., a gene derived from humans (in the case of a non-human cell). The CLAX
5 transgene can be misexpressed, e.g., overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpresses an endogenous CLAX gene, e.g., a gene that increases expression of an endogenous CLAX gene, or a gene the expression of which is disrupted, e.g., a knockout. Such cells can serve as a model for studying disorders which are related to mutated or
10 misexpressed CLAX alleles for use in drug screening.

Still further, the invention provides plasmids that comprise the nucleic acid molecules of the invention.

The present invention also includes a novel CLAX of the present invention, or an active part thereof. A biologically competent or active form of the protein or part
15 thereof is also referred to herein as an "active CLAX or part thereof".

The invention further contemplates antibodies having specificity against an epitope of the CLAX protein of the present invention, or part of the protein. These antibodies may be polyclonal or monoclonal. The antibodies may be labeled with a detectable substance and they may be used, for example, to detect the novel CLAX of
20 the invention in tissue and cells. Additionally, the antibodies of the present invention, or portions thereof, may be used to make targeted antibodies that destroy CLAX expressing cells (e.g., antibody-toxin fusion proteins, or radiolabelled antibodies).

The invention also permits the construction of nucleotide probes that encode part or all of the novel CLAX protein of the invention or a part of the protein. Thus,
25 the invention also relates to a probe comprising a nucleotide sequence coding for a protein, which displays the properties of the novel CLAX of the invention or a peptide unique to the protein. The probe may be labeled, for example, with a detectable (e.g., radioactive) substance and it may be used to select from a mixture of nucleotide sequences a nucleotide sequence coding for a protein which displays the
30 properties of the novel CLAX protein of the invention.

The present invention also provides a transgenic non-human animal (e.g., a rodent, e.g., a mouse or a rat, a rabbit or a pig) or embryo all of whose germ cells and somatic cells contain a recombinant molecule of the invention, preferably a recombinant molecule comprising a nucleic acid molecule of the present invention encoding a CLAX of the invention or part thereof. The recombinant molecule may comprise a nucleic acid sequence encoding the CLAX of the present invention with a structural mutation, or may comprise a nucleic acid sequence encoding the CLAX protein of the invention or part thereof and one or more regulatory elements which differ from the regulatory elements that drive expression of the native protein. In another preferred embodiment, the animal has a CLAX gene that is misexpressed (e.g., over-expressed) or not expressed (e.g., a knockout). Such transgenic animals can serve as models for studying disorders that are related to mutated or misexpressed CLAX of the present invention.

The invention still further provides a method for identifying a substance which is capable of binding to and/or modulating the novel CLAX of the present invention, said method comprising reacting the novel CLAX of the invention or part of the protein under conditions which permit the formation of a complex between the substance and the novel CLAX protein or part of the protein, and assaying for substance-CLAX complexes, for free substance, for non-complexed CLAX, or for activation of the CLAX.

An embodiment of the invention provides a method for identifying ligands which are capable of binding to the novel CLAX protein of the invention, isoforms thereof, or part of the protein, said method comprising reacting the novel CLAX protein of the invention, isoforms thereof, or part of the protein, with at least one ligand which potentially is capable of binding to the protein, isoform, or part of the protein, under conditions which permit the formation of ligand-receptor protein complexes, and assaying for ligand-receptor protein complexes, for free ligand, for non-complexed CLAX protein, or for activation of the CLAX protein. In a preferred embodiment of the method, ligands are identified which are capable of binding to and activating or inactivating the novel CLAX protein of the invention, isoforms thereof, or part(s) of the protein.

The invention also relates to a method for assaying a medium for the presence of an agonist or antagonist of the interaction of the novel CLAX protein and a substance which is capable of binding the CLAX, said method comprising providing a known concentration of a CLAX protein, reacting the CLAX with a substance
5 which is capable of binding to the CLAX and a suspected agonist or antagonist under conditions which permit the formation of substance-CLAX complexes, and assaying for substance-CLAX complexes, for free substance, for non-complexed CLAX, or for activation of the CLAX protein.

The invention further provides a method for identifying a substance which is
10 capable of binding to an activated CLAX protein of the present invention or an isoform or a part of the protein, said method comprising reacting an activated CLAX of the present invention, or an isoform or part of the protein, with at least one substance which potentially can bind with the CLAX, isoform or part of the protein, under conditions which permit the formation of substance-activated CLAX
15 complexes, and assaying for substance-CLAX complexes, for free substance, or for non-complexed CLAX. The method may be used to identify intracellular ligands containing proteins that bind to an activated CLAX protein of the present invention or parts thereof, or intracellular ligands that may be affected in other ways by the activated CLAX of the invention.

Also included within the scope of the present invention is a composition
20 which includes a CLAX of the present invention, a fragment thereof (or a nucleic acid encoding said CLAX or fragment thereof) and, optionally, one or more additional components, e.g., a carrier, diluent or solvent. The additional component can be one that renders the composition useful for in vitro, in vivo, pharmaceutical or veterinary
25 use.

In another aspect, the present invention relates to a method of treating a mammal, e.g., a human, at risk for a disorder, e.g., a disorder characterized by aberrant or unwanted level or biological activity of the CLAX of the present invention, or characterized by an aberrant or unwanted level of a ligand that
30 specifically binds to a CLAX of the present invention. For example, the CLAX of the present invention may be useful to leach out or block a ligand which is found to bind

to the CLAX of the present invention. Encompassed within the scope of the invention is a soluble form of the CLAX protein of the present invention, e.g., a fragment of the receptor, that may be used to inhibit activation of the receptor by binding to the ligand a polypeptide of the present invention and preventing the ligand from interacting with membrane bound CLAX.

Also within the scope of the present invention are fusion proteins comprising all or a portion of the CLAX of the present invention. Preferably, the fusion protein comprises all or a portion of the extracellular region of the CLAX of the present invention as shown in SEQ ID NO:2. All or a portion of the extracellular portion of the CLAX of the present invention may be attached to another molecule or polypeptide, e.g., a hinge and/or constant region of an immunoglobulin ("Ig") protein. Also included within the present invention are soluble fusion proteins comprising all or a portion of CLAX, and additionally comprising an extracellular domain of another receptor molecule (e.g., an extracellular domain of murine CD8 at the N-terminal side and an extracellular domain of CLAX at the C-terminal side). Examples of soluble fusion proteins are given in Figure 4.

The primary object of the present invention is the identification of a new human CLAX, as identified by its sequence disclosed herein. Additional objects of the invention are the methods of using the cDNA, the CLAX protein, a monoclonal antibody specific for the novel CLAX, fusion proteins comprising a portion of the CLAX protein of the present invention, and a ligand for the novel CLAX as described above.

Brief description of the drawings

Figure 1 is a schematic representation of the cloning strategy for the CLAX proteins of the present invention. The initial part of nucleic acid sequences coding for human CLAX was obtained by homology search of human CD69 cDNA from EST database of The Institute for Genomic Research (TIGR). Contig of ESTs was assembled by using databases from TIGR and Incyte Pharmaceuticals, Palo Alto, CA.

Figure 2A gives the nucleotide sequence (SEQ ID NO:1) and the deduced amino acid sequence (SEQ ID NO:2) of the CLAX protein of the present invention.

Figure 2B gives the nucleotide sequence (SEQ ID NO:3) and the deduced amino acid sequence (SEQ ID NO:4) of clone 7B encoding a CLAX homologue of
5 the present invention.

Figure 2C gives the nucleotide sequence (SEQ ID NO:5) and the deduced amino acid sequence (SEQ ID NO:6) of clone 2I encoding a CLAX homologue of the present invention.

Figure 2D gives the nucleotide sequence (SEQ ID NO:7) and the deduced amino acid sequence (SEQ ID NO:8) of clone 4A encoding a CLAX homologue of
10 the present invention.

Figure 3A is a comparison of the predicted amino acid sequences of CLAX homologues. The amino acids comprising the transmembrane region are determined by Kyte-Doolittle hydropathy plot as indicated with one solid underline. The charged
15 arginine residue in the transmembrane region is in bold and underlined. The conserved cysteine residues are in bold. The putative N-linked glycosylation sites are underlined with two solid lines. The amino acid sequences of CLAX clone 2I and clone 4A that are different from the amino acid sequence of CLAX clone 7B are italicized.

Figure 3B shows the amino acid sequence alignment of the C-type lectin domains of CLAX clones 7B, 2I and 4A with human CD69, chicken 17.5, human AICL, human ASGPR, human CD94, human MAFA and human CD23. Asterisks indicate conserved amino acid residues. Bold indicates the amino acid motifs that are conserved in the C-type lectin domain.
20

Figure 4 shows the amino acid sequences of soluble fusion proteins of CLAX protein, designated as CLAX-18, CLAX-5 and CLAX-13. The amino acid sequences encoding for the extracellular domains of CLAX-18, -5 and -13 are in bold. The amino acid sequences of CLAX-5 and -13 which are different from the amino acid sequences of CLAX-18 are underlined.
25

Figures 5A and 5B show Northern blot analysis of CLAX expression in
30 different tissues. 2.5 µg of poly-adenylated RNA from the indicated human tissues

was used to prepare Northern blots (Clontech, Palo Alto, CA). The blots were hybridized with a ^{32}P labeled cDNA probe corresponding to a cDNA fragment of CLAX-18 and visualized by autoradiography. Position of RNA standards is indicated on the left in kb. Two transcripts of approximately 2.5 kb and 4.0 kb are indicated by arrows on the right. The transcripts were detected in lymphoid tissues (with the exception of bone marrow and fetal liver) and not detected in non-lymphoid tissues (prostate, testis, ovary, small intestine and colon).

Figure 6 shows a Northern blot analysis of transcription kinetics of CLAX gene during T lymphocyte activation. Human T lymphocytes were activated by immobilized anti-CD3 mAb. 25 μg of total RNA from the indicated time point of activation was loaded at each lane in a Northern blot. The RNA were subjected to electrophoresis through a denaturing 1.2% agarose, 6% formaldehyde gel and transferred to an Optitran nitrocellulose membrane. The blots were hybridized with a ^{32}P labeled cDNA probe corresponding to a cDNA fragment CLAX-18 and visualized by autoradiography. Position of RNA standards is indicated on the left in kb. Two transcripts of approximately 2.5 kb and 4.0 kb were detected in activated T lymphocytes (8, 24, 48 and 72 hours) but not in resting T lymphocytes (0 hour).

Detailed description of the invention

The present invention provides a nucleic acid and amino acid sequence of a novel CLAX protein, as well as the nucleic acid and amino acid sequences of three CLAX homologues.

The nucleic acids of the present invention can be used in a variety of ways in accordance with the present invention. For example, they can be used as DNA probes to screen other cDNA and genomic DNA libraries so as to select by hybridization other DNA sequences that code for proteins related to CLAX and its variants. In addition, the nucleic acids of the present invention can be used as DNA probes to screen other cDNA and genomic DNA libraries to select by hybridization other DNA sequences that code for proteins of CLAX and its variants from other organisms. The nucleic acid probes can be RNA or DNA, and may or may not be labeled with radioactive nucleotides, or may be used in non-radioactive methods (i.e., biotin).

Screening can be done at various stringency conditions (through manipulation of the hybridization T_m , usually using a combination of ionic strength, temperature and/or presence of formamide) to isolate close or distantly related homologues. Stringency conditions under which a nucleic acid sequence of at least 18 nucleic acids from SEQ ID NO:1 would hybridize to the nucleic acid sequences disclosed herein are, for example, 50% formamide, 5x SSPE (750 mM NaCl, 50 mM NaH_2PO_4 and 5 mM EDTA), 5x Denhardt's solution, 0.1% SDS and 100 $\mu\text{g/ml}$ denatured, sheared salmon sperm DNA.

The nucleic acids may also be used to generate primers to amplify cDNA or genomic DNA using polymerase chain reaction (PCR) techniques. The nucleic acid sequences of the present invention can also be used to identify adjacent sequences in the cDNA elements. In addition, the nucleic acid sequences of the present invention can be used diagnostically to detect nucleic acid sequences encoding CLAX and its variants in diseases of inflammation and allergy. Detection of such mutations can be determined by standard DNA analysis techniques, including genomic and /or cDNA sequencing, SSCP and Southern blot.

The nucleic acid sequences encoding CLAX and the homologues disclosed herein provide the means for obtaining CLAX protein, a homologue thereof, and/or a soluble form of CLAX and its homologues/variants. The polypeptides and soluble forms of CLAX of the present invention are useful in the study of the characteristics of CLAX, for example, its structure, mechanism of action, and role in inflammation and allergy. The soluble form of CLAX and its variants can be used to generate monoclonal and polyclonal antibodies. The CLAX proteins and its homologues can be detected using monoclonal and polyclonal antibodies for diagnosis of diseases of inflammation and allergy by using ELISA, immunoprecipitation, immunohistochemistry, or Western blot analysis. CLAX proteins can be studied to further delineate functional domains, and thus can be used to model compounds with similar activity. In addition, the CLAX protein and homologues disclosed herein can be used in *in vivo* cell based and in *in vitro* cell free assays to screen natural products and synthetic compounds that might mimic, regulate or otherwise modulate (e.g., agonists and/or antagonists) CLAX protein function.

Various other methods of using the nucleic acids and polypeptides of the present invention are described in detail below.

Nucleic acids

5 The present invention provides a nucleic acid sequence encoding a novel CLAX protein, as well as nucleic acid sequences for three CLAX homologues. Preferably, the nucleic acid molecule is a DNA molecule. A preferred embodiment of the invention provides a nucleic acid sequence (SEQ ID NO:1) comprising nucleotides 6 through 587 of the sequence shown below (SEQ ID NO:9):

10	GCAAA ATG CAT GAC AGT AAC AAT GTG GAG AAA GAC ATT ACA	41
	CCA TCT GAA TTG CCT GCA AAC CCA GGT TGT CTG CAT TCA AAA	83
	GAG CAT TCT ATT AAA GCT ACC TTA ATT TGG CGC TTA TTT TTC	125
	TTA ATC ATG TTT CTG ACA ATC ATA GTG TGT GGA ATG GTT GCT	167
	GCT TTA AGC GCA ATA AGA GCT AAC TGC CAT CAA GAG CCA TCA	209
15	GTA TGT CTT CAA GCT GCA TGC CCA GAA AGC TGG ATT GGT TTT	251
	CAA AGA AAG TGT TTC TAT TTT TCT GAT GAC ACC AAG AAC TGG	293
	ACA TCA AGT CAG AGG TTT TGT GAC TCA CAA GAT GCT GAT CTT	335
	GCT CAG GTT GAA AGC TTC CAG GAA CTG AAT TTC CTG TTG AGA	377
	TAT AAA GGC CCA TCT GAT CAC TGG ATT GGG CTG AGC AGA GAA	419
20	CAA GGC CAA CCA TGG AAA TGG ATA AAT GGT ACT GAA TGG ACA	461
	AGA CAG TTA GTC ATG AAA GAA GAT GGT GCC AAC TTG TAT GTT	503
	GCA AAG GTT TCA CAA GTT CCT CGA ATG AAT CCA AGA CCT GTC	545
	ATG GTT TCC TAT CCT GGG AGC AGG AGA GTG TGC CTA TTT GAA	587
	TGACAAAGGT GCCAGTAGTG CCAGGCACTA CACAGAGAGG AAGTGGATTT	637
25	GTTCCAAATC AGATATACAT GTCTAGATGT TACAGCAAAG CCCCAACTAA	687
	TCTTTAGAAG CATATTGGAA CTGATAACTC CATTTTAAAA TGAGCAAAGA	737
	ATTTATTTCT TATACCAACA GGTATATGAA AATATGCTCA ATATCACTAA	787
	TAACTGGGAA AATACAATCA AAATCATAGT AAAATATTAC CTGTTTTTCAT	837
	GGTGCTAATA TTACCTGTTC TCCCACTGCT AATGACATAC CCGAGACTGA	887
30	GTAATTTATA AATAAAAGAG ATTTAATTGA AAAAAAAAAA AAAA	931

Also within the scope of the present invention are nucleic acid sequences encoding homologues of the CLAX protein, for example the nucleic acid sequence of CLAX clone 7B (SEQ ID NO:3), the nucleic acid sequence of CLAX clone 2I (SEQ

ID NO:5), and the nucleic acid sequence of CLAX clone 4A (SEQ ID NO:7).

Preferred are the coding regions of the above referenced sequences.

Also encompassed within the scope of the present invention are nucleic acid sequences complementary to one of these nucleic acid sequences. Additionally
5 preferred are nucleic acid sequences that hybridize to one of these nucleic acid sequences. In the case of nucleotide sequences (e.g., a DNA sequence) that will hybridize to the sequences provided herein coding for CLAX and its homologues, it is preferred that the nucleotide sequence be at least about 15 sequential nucleotides in length, more preferably about 18 sequential nucleotides in length, more preferably at
10 least about 20 to 30 sequential nucleotides in length (said sequential nucleotides contained in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9).

Also within the present invention are nucleic acid sequences that differ from the nucleic acid sequences disclosed herein due to degeneracy of the genetic code
15 (i.e., nucleic acid sequences that encode amino acid sequences identical to the amino acid sequences encoded by the nucleic acid sequences provided herein).

The nucleic acids of the present invention can be isolated from a variety of sources, although the presently preferred sequences have been isolated from a human cDNA library. The exact amino acid sequences of the polypeptide molecules
20 produced will vary with the initial DNA sequences.

The nucleic acids of the present invention can be obtained using various methods well known to those of ordinary skill in the art, for example, but not limited to, the following methods: (1) the isolation of double-stranded DNA sequence from genomic DNA or complementary DNA (cDNA) which contains the sequences; (2)
25 the chemical synthesis of the DNA sequences; and (3) the synthesis of the DNA sequences by polymerase chain reaction (PCR).

In the first method, a genomic or cDNA library can be screened in order to identify a DNA sequence coding for all or part of CLAX and/or its homologues. Various techniques can be used to screen genomic DNA or cDNA libraries for
30 sequences that code for novel CLAX proteins. This technique may, for example, employ a labeled single-stranded DNA probe with a sequence complementary to a

sequence that codes for CLAX. For example, DNA/DNA hybridization procedures may be used to identify the sequence in cloned copies of genomic DNA or cDNA that have been denatured to a single-stranded form. Suitable probes include cDNA for CLAX and its variants acquired from the same or a related species, synthetic
5 oligonucleotide, and the like. A genomic or cDNA library can be screened in order to identify a DNA sequence coding for sequences flanking such coding sequences, using immunoblotting techniques.

In one typical screening method suitable for the hybridization techniques, a genomic DNA or cDNA library is first spread out on agar plate, and then the clones
10 are transferred to filter membranes, for example, nitrocellulose membranes. The genomic library is usually contained in a vector such as EMBL 3 or EMBL 4 or derivatives, or in cosmid libraries, P1 phage libraries or YAC libraries. The cDNA library is usually contained in a vector such as λ gt10, λ gt11, or λ Zap. A DNA probe can then be hybridized to the clones to identify those clones containing the genomic
15 DNA or cDNA coding for all or part of CLAX and its homologues. Alternatively, appropriate *E. coli* strains containing vectors such as λ gt11 or λ Zap can be induced to synthesize fusion proteins containing fragments of proteins corresponding to the cDNA insert in the vector. The fusion proteins may be transferred to filter membranes, for example, nitrocellulose. An antibody may then be bound to the fusion
20 protein to identify all or part of CLAX and/or its homologues.

In a second method, the nucleic acids of the present invention coding for CLAX and its variants can be chemically synthesized. Shorter oligonucleotide, such as 15 to 50 nucleotides, may be directly synthesized. For longer oligonucleotides, the DNA sequence coding for CLAX and/or its homologues can be synthesized as a
25 series of 50-100 base oligonucleotides that can then be sequentially ligated (via appropriate terminal restriction sites) so as to form the correct linear sequence of nucleotides.

In a third method, the nucleic acids of the present invention coding for CLAX and/or its homologues can be synthesized using PCR. Briefly, pairs of synthetic
30 DNA oligonucleotides, generally at least 15 bases in length (PCR primers) that hybridize to opposite strands of the target DNA sequence, are used to enzymatically

amplify the intervening region of DNA on the target sequence. Repeated cycles of heat denaturation of the template, annealing of the primers and extension of the 3'-termini of the annealed primers with a DNA polymerase, result in amplification of the segment defined by the PCR primers.

5 The nucleic acids of the present invention coding for CLAX and its homologues can also be modified (i.e., mutated) to prepare various additional biologically active analogues of CLAX or its homologues disclosed herein. Such mutations may change the amino acid sequence encoded by the mutated codon, or they may be silent and not change the amino acid sequence. These modified nucleic acids may be prepared, for example, by mutating the nucleic acids coding for CLAX and its homologues so that the mutation results in the deletion, substitution, insertion or addition of one or more amino acids in the encoded polypeptide using various methods known in the art. For example, the methods of site-directed mutagenesis may be employed. In addition, kits for site-directed mutagenesis may be purchased from commercial vendors. Disruption, deletion and truncation methods may also be employed. Mutations may be advantageous in producing or using the polypeptides of the present invention. For example, these mutations may modify the function of the protein (e.g. result in higher or lower activity), permit higher levels of protein production or easier purification of the protein, or provide additional restriction endonuclease recognition sites in the nucleic acids. All such modified nucleic acid and polypeptide molecules are included within the scope of the present invention. As used in the present application, unless otherwise limited in specific instances, the term "modified", when referring to a nucleotide or polypeptide sequence, means a nucleotide or polypeptide sequence which differs from the wild-type sequence found in nature.

Expression vectors

 The present invention further concerns expression vectors comprising a DNA sequence coding for all or part of CLAX and its homologues. The expression vectors preferably contain all or part of the DNA sequences having the nucleotide sequences shown in Figure 2A-2D (SEQ ID NO:1; SEQ ID NO:3; SEQ ID NO:5; SEQ ID

NO:7; and SEQ ID NO:9). Further preferred are expression vectors comprising one or more regulatory DNA sequences operatively linked to the DNA sequence coding for all or part of the CLAX and its variants. As used in this context, the term “operatively linked” means that the regulatory DNA sequences are capable of directing the replication and /or the expression of the DNA sequence coding for all or part of CLAX and/or its homologues.

Expression vectors of utility in the present invention are often in the form of “plasmids”, which refer to circular double stranded DNA loops that, in their vector form, are not bound to the chromosome. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto. The expression vectors of the present invention may also be used for the stable integration of the DNA sequence encoding CLAX or its homologues into the chromosome of an appropriate host cell (e.g. CHO, Jurkat and EB cells).

Expression vectors useful in the present invention typically contain an origin of replication, a promoter located 5' to (i.e., upstream of) and followed by the DNA sequence coding for all or part of CLAX and/or its homologues, transcription termination sequence, and the remaining vector. The expression vectors may also include other DNA sequence known in the art, for example, stability leader sequences that provide for stability of the expression product, secretory leader sequences which provide for secretion of the expression product, sequences which allow expression of the structural gene to be modulated.

Gene constructs of the present invention can also be used as part of a gene therapy protocol to deliver nucleic acids encoding CLAX and/or a homologue thereof of the present invention, or an agonist or antagonist form of a CLAX protein or peptide. The invention features expression vectors for *in vivo* transfection and expression of a CLAX protein. Expression constructs of the CLAX protein of the present invention, may be administered in any biologically effective carrier, e.g., any formulation or composition capable of effectively delivering the CLAX gene to cells *in vivo*. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenoviruses, adeno-associated viruses, and herpes simplex

virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; an advantage of infection of cells with a viral vector is that a large proportion of the targeted cells can receive the nucleic acid. Several viral delivery systems are known in the art and can be utilized by one practicing the present invention.

In addition to viral transfer methods, non-viral methods may also be employed to cause expression of the CLAX gene in the tissue of an animal. Most non-viral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. DNA of the present invention may also be introduced to cell(s) by direct injection of the gene construct or electroporation.

In clinical settings, the gene delivery systems for the therapeutic CLAX gene can be introduced into a patient by any of a number of methods, each of which is known in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g., by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof.

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is embedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

Another aspect of the invention relates to the use of an isolated nucleic acid in "antisense" therapy. As used herein, "antisense" therapy refers to administration or in situ generation of oligonucleotides or their derivatives which specifically hybridize under cellular conditions, with the cellular mRNA and/or genomic DNA encoding CLAX or homologue thereof of the present invention so as to inhibit expression of

the encoded protein, e.g., by inhibiting transcription and/or translation. In general, “antisense” therapy refers to the range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

5

Polypeptides

The present invention further encompasses polypeptide molecules comprising all or a portion of CLAX and/or its homologues, said polypeptide molecules preferably having all or part of the amino acid sequence as shown in Figure 2A (SEQ ID NO:2) and Figure 3 (SEQ ID NO:4; SEQ ID NO:6; and SEQ ID NO:8). In the case of polypeptide molecules comprising part of CLAX and/or a homologue thereof, it preferred that polypeptide molecules be at least about 5 to 8 sequential amino acids in length, more preferably at least about 15 to 20 sequential amino acids in length.

All amino acid sequences are represented herein by formulas whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus.

Polypeptides of the present invention may be obtained by synthetic means, i.e., chemical synthesis of the polypeptide from its component amino acid, by methods known to those of ordinary skill in the art. For example, the solid phase procedure may be employed. The polypeptides may also be obtained by production in prokaryotic or eukaryotic host cells expressing a DNA sequence coding for all or part of CLAX and/or a homologue thereof. The polypeptides may be translated *in vitro* from mRNA encoded by a DNA sequence coding for all or part of CLAX and/or a homologue thereof. For example, the nucleotide sequence as shown in SEQ ID NO:1 may be synthesized using PCR as described above and inserted into a suitable expression vector, which in turn may be used to transform a suitable host cell. The recombinant host cell may then be cultured to produce CLAX and/or its homologues. Techniques for the production of polypeptides by these means are known in the art, and are described herein.

The polypeptides produced in this manner may then be isolated and purified to some degree using various protein purification techniques. For example,

chromatographic procedures such as ion exchanges, gel filtration and immunoaffinity may be employed.

The polypeptides of the present invention may be used in wide variety of ways. For example, the polypeptides may be used to prepare in a known manner polyclonal or monoclonal antibodies capable of binding the polypeptides. These
5 antibodies may in turn be used for the detection of the polypeptides of the present invention in a sample (e.g., a cell sample) using immunoassay techniques, radioimmunoassay, enzyme immunoassay, or immunocytochemistry. The antibodies may also be used in affinity chromatography for isolating or purifying the
10 polypeptides of the present invention from various sources.

The polypeptides of the present invention have been defined by means of determined DNA and deduced amino acid sequencing. Due to the degeneracy of the genetic code, other DNA sequences which encode the same amino acid sequences depicted in Figure 2 and Figure 3, or any part thereof, may be used for the production
15 of the polypeptides of the present invention.

The present invention further relates to CLAX protein and homologues thereof which have the amino acid sequences encoded by the deposited cDNA clones, as well as fragments, analogs and derivatives of such polypeptide. Encompassed within the scope of the present invention are polypeptides as shown in SEQ ID NO:4,
20 SEQ ID NO:6 and SEQ ID NO:8.

The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-Organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under
25 U.S.C. §112. The sequence(s) of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

30 Analogues of the novel CLAX protein and homologues disclosed herein are also within the scope of the present invention. Analogs can differ from the naturally

occurring proteins of the present invention in amino acid sequence or in ways that do not involve sequence, or both. Non-sequence modifications include in vivo or in vitro chemical derivitization of the CLAX proteins of the present invention. Non-sequence modifications include changes in acetylation, methylation, phosphorylation, carboxylation, or glycosylation.

Preferred analogs include the novel CLAX and homologue proteins of the present invention (or biologically active fragments thereof) whose sequences differ from the wild-type sequence by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the biological activity of the proteins of the present invention. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative amino acid substitutions can be taken from the table below.

Table 1
Conservative amino acid replacements

For Amino Acid	Code	Replace with any of:
Alanine	A	D-Ala, Gly, beta-Ala, L-Cys, D-Cys
Arginine	R	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn
Asparagine	N	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Aspartic Acid	D	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Cysteine	C	D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr
Glutamine	Q	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Glutamic Acid	E	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Glycine	G	Ala, D-Ala, Pro, D-Pro, β -Ala, Acp
Isoleucine	I	D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met
Leucine	L	D-Leu, Val, D-Val, Met, D-Met
Lysine	K	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Methionine	M	D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val
Phenylalanine	F	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline
Proline	P	D-Pro, L-1-thioazolidine-4-carboxylic acid, D- or L-1-oxazolidine-4-carboxylic acid
Serine	S	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys
Threonine	T	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Tyrosine	Y	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Valine	V	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met

- 5 Other analogs within the invention are those with modifications which increase protein or peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the protein or peptide sequence. Also included are analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic
- 10 amino acids, e.g., β or γ amino acids.

Other contemplated variations include salts and esters of the aforementioned polypeptides, as well as precursors of the aforementioned polypeptides, for example, precursor having N-terminal substituents such as methionine, N-formylmethionine

and leader sequences. All such variations are included within the scope of the present invention.

The present invention also relates to methods of screening. Various techniques are known in the art for screening generated mutant gene products.

5 Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., in this case binding of a ligand to the CLAX proteins of the present invention. Techniques known in the art are amenable to high through-put
10 analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two hybrid assays can be used to identify fragments or analogs of a protein or peptide which bind to the CLAX protein or homologues of the present invention. These may include agonists or antagonists. In one approach to screening assays, the
15 candidate protein or peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologues. Fluorescently labeled ligands, e.g., receptors, can be used to
20 detect homologue which retain ligand-binding activity. The use of fluorescently labeled ligand allows cells to be visually inspected and separated under fluorescence microscope or to be separated by a fluorescence-activated cell sorter.

High through-put assays can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to
25 differentiate agonists from antagonists. The type of a secondary screen used will depend on the desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between the CLAX of the present invention and its respective ligand can be used to identify antagonists from a group of peptide fragments isolated through one of the primary screens. Therefore,
30 methods for generating fragments and analogs and testing them for activity are known

in the art. Once a sequence of interest is identified, it is routine for one skilled in the art to obtain agonistic or antagonistic analogs, fragments, and/or ligands.

Drug screening assays are also provided in the present invention. By producing purified and recombinant CLAX of the present invention, or fragments thereof, one skilled in the art can use these to screen for drugs which are either agonists or antagonists of the normal cellular function or their role in cellular signaling. In one embodiment, the assay evaluates the ability of a compound to modulate binding between the CLAX of the present invention and a naturally occurring ligand. The term "modulating" encompasses enhancement, diminishment, activation or inactivation of the CLAX protein. Assays useful to identify ligands to the CLAX protein of the present invention, including peptides, proteins, small molecules, and antibodies that are capable of binding to the CLAX protein are encompassed herein. A variety of assay formats will suffice and are known by those skilled in the art.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as primary screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound.

Also within the scope of the present invention is a process for modulating the CLAX protein of the present invention. Ligands to the CLAX protein of the present invention, including peptides, proteins, small molecules, and antibodies, that are capable of binding to the CLAX receptor and modulating its activity are encompassed herein. These compounds are useful in modulating the activity of the CLAX protein and in treating CLAX-associated disorders. "CLAX-associated disorders" refers to any disorder or disease state in which the CLAX protein plays a regulatory role in the metabolic pathway of that disorder or disease. Such disorders or diseases may include infection, autoimmune diseases and allergy. As used herein the term "treating" refers to the alleviation of symptoms of a particular disorder in a patient,

the improvement of an ascertainable measurement associated with a particular disorder, or the prevention of a particular immune, inflammatory or cellular response (such as transplant rejection).

The invention also includes antibodies specifically reactive with the CLAX protein of the present invention, or a portion thereof. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard known procedures. A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the polypeptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques known in the art. An immunogenic portion of the CLAX of the present invention can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with the CLAX protein and/or homologues of the present invention. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as whole antibodies. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments. The antibody of the present invention is further intended to include chimeric and humanized molecules that recognize and bind to the CLAX proteins of the present invention.

Both monoclonal and polyclonal antibodies directed against the CLAX proteins of the present invention, and antibody fragments such as Fab', sFv and F(ab')₂, can be used to block the action of the CLAX proteins of the present invention and allow study of the role of a particular CLAX or homologue of the present invention. Alternatively, such antibodies can be used therapeutically to block the CLAX protein of the present invention in a subject mammal, e.g., a human. In a preferred embodiment therapeutic compositions comprising an antibody of the present invention can also comprise a pharmaceutically acceptable carrier, solvent or diluent, and be administered by systems known in the art.

Antibodies of the present invention may also be useful as potential agonists of the CLAX proteins of the present invention. Such agonistic antibodies tend to aggregate and crosslink the receptor, which induces signaling, proliferation, differentiation and/or cell death (apoptosis).

- 5 Antibodies that specifically bind to the CLAX proteins of the present invention, or fragments thereof, can also be used in immunohistochemical staining of tissue samples in order to evaluate the abundance and pattern expression of the CLAX of the present invention. Antibodies can be used diagnostically in immunoprecipitation, immunoblotting, and enzyme linked immunosorbent assay
- 10 (ELISA) to detect and evaluate levels of the CLAX proteins of the present invention in tissue or bodily fluid.

The following examples further illustrate the present invention. These examples are not intended to limit the scope of the present invention, and may provide further understanding of the invention.

15

EXAMPLE I

Identification of Novel CLAX and Its Variants

1. Bioinformatics

CD69 is widely expressed on hematopoietic cells including lymphocytes,
5 neutrophils, eosinophils, platelets and epidermal langerhans cells. It is not expressed
on resting but is rapidly induced upon activation. CD69 is the earliest activation
marker of lymphocytes. Anti-CD69 mAb can induce activation and cytokine
production of T, B and NK cells. These functions may shed light on its homologues.

A full-length polypeptide sequence of human CD69 was used as a query
10 sequence searching for nucleotide sequences (six-frame translations) against TIGR
Expressed Sequence Tag (EST) database. Two relevant ESTs from activated T cells
were identified by doing TBLASTN software program (Basic Local Alignment
Search Tool). The ESTs were retrieved using ENTREZ at
<http://www.ncbi.nlm.nih.gov/Entrez>. The retrieved ESTs were imported into the
15 LifeSeq program of Incyte Pharmaceuticals and used as query nucleotide sequences
searching for Incyte EST database. Five more ESTs were identified by using
TBLASTX software program. The 7 ESTs were assembled into a single contiguous
project (Contig) by using GCG assembly software (Figure 1). The contig cDNA
encodes a novel type II membrane protein and belongs to the C-type lectin
20 superfamily (Figure 2A). Its deduced amino acid sequence is 41% amino acid
identical to those of human CD69, the closest one in amino acid sequence. This novel
cDNA was labeled as "CLAX" protein by the inventors.

2. PCR cloning of extracellular domain of CLAX

25 According to nucleotide sequence of the CLAX contig, the sense primer
oligonucleotide (5'-CTAGGATCCAAGAGCTAACTGCCATCAAGAGCC-3')
(SEQ ID NO:10) with a restriction site for *Bam*HI and the antisense primer (5'-
CATTCTAGATGCCTGGCACTACTGGCACCTTTG-3') (SEQ ID NO:11) with a
restriction site for *Xba*I were synthesized by Life Technologies, Gaithersburg, MD.
30 A DNA fragment encoding for the extracellular domain of CLAX was amplified by
reverse transcription-coupled PCR from RNA prepared from LPS-activated human

THP-1 cells. The PCR product was cloned directly into the vector CDM7B-, which contains cDNA of the extracellular domain of mouse CD8 in upstream of the restriction site for *BamHI*. The inserted DNA in the CDM7B-CLAX construct (CLAX-18) was sequenced in both strands by the dideoxy chain termination method
5 and is identical to DNA segment of the contig of CLAX.

3. Isolation of cDNA encoding CLAX and its variants

A λ TriplEx cDNA library derived from human leukocytes was purchased from Clontech, Palo Alto, CA. The library was screened with [32 P] dCTP random
10 prime-labeled DNA probe that was generated by purification of the *BamHI-XbaI* cDNA fragment from CLAX-18 construct. The nylon transfer membranes were hybridized in hybridization solution 1 at 42°C for 16 h according to the manufacturer's recommendations. After hybridization, the membranes were washed with 3 changes in 2X SSC and 0.1% SDS for 30 min at room temperature and then in
15 1X SSC and 0.1% SDS for 60 min at 65°C. The positive plaques were plated and screened for second round hybridization with the same CLAX-18-specific DNA probe. The positive λ TriplEx plaques were further converted into plasmid clones of pTriplEx in different host *E. coli* provided by Clontech. The cDNAs from isolated pTriplEx were sequenced in both strands by the dideoxy chain termination method.
20 Three clones encoding different extracellular domains of CLAX were identified. Clone 7B encodes the sequence that matches to the contig of CLAX. Clone 2I has a frame-shift in its ORF, resulting in a different polypeptide from clone 7B at the last 37 amino acid residues of C-terminal. Clone 4A contains a truncation within its extracellular domain. The parts of DNA sequence of clone 7B, clone 2I and clone 4A
25 match to the DNA sequences of clones isolated by PCR cloning. Since all three forms of CLAX can be produced by both screen of cDNA library and PCR cloning, the results suggest that CLAX and its homologues naturally exist. The different forms of cDNA may be due to the result of alternative splicing.

4. Determination of the CLAX cDNA sequence

The complete nucleotide sequence (SEQ ID NO:9) of the CLAX cDNA is depicted in Figure 2A. An open reading frame deduced from the nucleotide sequence starts at nucleotide #6 with a codon for methionine and ends at nucleotide #587

5 before a TGA stop codon (SEQ ID NO:1 gives the reading frame). The Kyte-Doolittle Hydropathy plot of the deduced amino acid sequence predicts a 26 amino acid long transmembrane domain (Figure 3A, underlined). A positively charged arginine residue is located within the transmembrane domain. There are two putative N-glycosylation sites in clone 7B and clone 2I and there is one putative N-
10 glycosylation site in clone 4A.

A search for homology to the CLAX cDNA nucleotide sequences indicated that the CLAX and its homologues are novel unknown genes. However, significant homology was found between the extracellular domain of CLAX-7B, 2I and 4A and the carbohydrate recognition domain (CRD) of several type II integral membrane
15 proteins that are members of the Ca^{2+} -dependent C-type lectin superfamily. Among them, human CD69 is the closest one with 41% amino acid identical to that of human CLAX-7B. Chicken17.5 is the closest one for CLAX-2I and 4A with 35% and 25% amino acid identity, respectively. Interestingly, these C-type lectins displaying high sequence homology with the CLAX CRD are all involved in immunological
20 functions. Most of these genes are located in the NK gene complex at human chromosome 12. Besides CD69 and Chicken17.5, these are the activation-induced C-type lectin (AICL), asialoglycoprotein, CD94, Mast cell function-associated antigen (MAFA), the type II receptor for IgE (Fc ϵ RII/CD23) and the natural killer antigens Ly-49. Amino acid sequence alignment of the CRD of the CLAX and of several of
25 the above-mentioned lectins shows the absolute conservation of 11 residues (4 tryptophans, 3 cysteines, and 2 glycines and 2 leucines) interspersed within this 76 to 79 amino acids long domain (Figure 3B). Furthermore, the WIGL and CFYFS amino acid motifs are highly conserved throughout these proteins.

EXAMPLE II

Cloning and Expression of the fusion proteins of CLAX and its Variants

1. Construction of the fusion proteins of CLAX and its Variants

DNA fragments encoding the extracellular domain of CLAX and its variants, which are CLAX-18, CLAX-13 and CLAX-5, were amplified by reverse transcription-coupled PCR as described above. The PCR products were cloned directly into the vector CDM7B-, which contains cDNA of the extracellular domain of mouse CD8 (mCD8) upstream of the *Bam*HI insertion site. As shown in Figure 4, the resulting constructs encode soluble fusion protein with mCD8 at the side of N-terminal and CLAX at the side of C-terminal. The inserted DNA segments in CDM7B- constructs were sequenced in both strands by the dideoxy chain termination method.

2. Transfection

The CDM7B-CLAX and its variant constructs were transiently transfected into COS-7 cells by the DEAE-dextran precipitation technique. Briefly, 75% confluent COS-7 cells were incubated in 5% NuSerum DMEM medium with mixture of DEAE-dextran/DNA for 3 hours and then shocked with 10% DMSO in PBS for 2 min. The cells were cultured in 10%FCS DMEM medium at 37°C overnight and then in serum-free DMEM medium for additional 7 days. Supernatant was collected for further analysis and purification.

3. Detection of fusion proteins by enzyme-linked immunosorbent assay (ELISA) and Western blot

The methods used here are designed to detect the mCD8 portion of the fusion proteins. The expression of CLAX fusion proteins in supernatant was first examined by ELISA. Briefly, Dynatech Immulon II 96-well plates were coated with 2 µg/ml of monoclonal antibody (mAb) 53.6 against mCD8 in carbonate/bicarbonate buffer (pH 9.6) for overnight at 4°C. The plates were blocked with LAV EIA specimen diluent for 1 hour and washed three times with PBS/Tween buffer. The supernatant samples at 100 µl per well were added and incubated for 1 hour at room temperature.

After incubation, the plates were washed and then 2 µg/ml of biotinylated detecting mAb 53.6 were added into the well. The samples were read out by color reaction, which is mediated by avidin-conjugated peroxidase added in the well. The supernatant samples and purified fusion proteins were also detected with mAb 53.6 by Western blot. Discontinuous SDS-PAGE was performed using 14% polyacrylamide gels.

4. Purification of fusion proteins of CLAX and its variants

The immunoaffinity columns were generated by immobilization of mAb 53.6 against mCD8 onto the protein-G sepharose beads. The 53.6-coated beads were covalently linked by the chemical linker DMPI (Pierce) and quenched in 0.2M ethanolamine (pH 8). Before loading sample onto the column, the beads were washed three times in PBS. The supernatants of CLAX-18, CLAX-13 and CLAX-5 were loaded onto the three individual columns, respectively. The columns were washed with 100 bed volumes of PBS. The fusion proteins of CLAX-18, CLAX-13 and CLAX-5 were eluted from the columns with elution buffer (35% propylene glycol in PBS containing 1.25 M ammonium sulfate, 20mM Hepes, 0.05% Azide).

EXAMPLE III

Expression of Genes of CLAX and Its Variants

1. Isolation of RNA and Northern blot analysis

25 µg of total RNA was subjected to electrophoresis through a denaturing 1.2% agarose, 5% formaldehyde gel and transferred to an Optitran nitrocellulose membrane (Schleicher & Schuell, Keene, NH). Equal loading of samples was confirmed by staining RNA with ethidium bromide. Human tissue mRNA blots were purchased from Clontech. Human CLAX-specific probe was generated by purification of the BamHI-XbaI cDNA fragment and labeled with [³²P] dCTP by using random prime-labeling kit. The membranes were hybridized in ExpressHyb solution at 68°C for 60 min. After hybridization, the membranes were washed with 3 changes in 2 X SSC and 0.1% SDS for 30 min at room temperature, and then in 1 X SSC and 0.1% SDS for 60 min at 65°C.

2. Isolation T lymphocytes from peripheral blood mononuclear cells and generation of antigen-nonspecific activated T lymphocytes

Peripheral blood mononuclear cells (PBMC) were obtained by using Ficoll-Hypaque density gradient centrifugation from three healthy donors. The PBMC were mixed with sheep red blood cells (SRBC) and spun at 1000 rpm for 5 min. The pellet was incubated on ice for 1 hour and followed by gentle resuspension with medium. The mixture of PBMC-SRBC was spun again with Ficoll-Hypaque density gradient. The SRBC-rosetted T lymphocytes in pellet were isolated by removing SRBC with hypotonic lysis. After washing twice with PBS, the T lymphocytes without incubation were referred as resting T cells (0 hour in Figure 6). The rest of the T lymphocytes were incubated in 6-well plates that were coated with anti-CD3 monoclonal antibody (G19-4). The cells were harvested at the different time point (8, 24, 48 and 72 hours in Figure 6). The total RNA of each sample was prepared and subjected to Northern blot analysis.

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

We claim:

1. A purified and isolated nucleic acid sequence encoding all or a portion
of a CLAX protein, said CLAX protein comprising the amino acid sequence as shown
5 in SEQ ID NO:2.

2. The nucleic acid sequence of claim 1 comprising (a) the nucleic acid
sequence as shown in SEQ ID NO:1; (b) the complement of (a); or (c) nucleic acid
sequences that differ from (a) or (b) due to degeneracy of the genetic code.
10

3. A purified and isolated nucleic acid sequence encoding all or a portion
of a CLAX protein homologue, said CLAX protein homologue comprising the amino
acid sequence as shown in SEQ ID NO:4.

4. The nucleic acid sequence of claim 3 comprising (a) the nucleic acid
sequence as shown in SEQ ID NO:3; (b) the complement of (a); or (c) nucleic acid
sequences that differ from (a) or (b) due to degeneracy of the genetic code.
15

5. A purified and isolated nucleic acid sequence encoding all or a portion
20 of a CLAX protein homologue, said CLAX protein homologue comprising the amino
acid sequence as shown in SEQ ID NO:6.

6. The nucleic acid sequence of claim 5 comprising (a) the nucleic acid
sequence as shown in SEQ ID NO:5; (b) the complement of (a); or (c) nucleic acid
25 sequences that differ from (a) or (b) due to degeneracy of the genetic code.

7. A purified and isolated nucleic acid sequence encoding all or a portion
of a CLAX protein homologue, said CLAX protein homologue comprising the amino
acid sequence as shown in SEQ ID NO:8.
30

8. The nucleic acid sequence of claim 7 comprising (a) the nucleic acid sequence as shown in SEQ ID NO:7; (b) the complement of (a); or (c) nucleic acid sequences that differ from (a) or (b) due to degeneracy of the genetic code.

5 9. An expression vector comprising a nucleic acid molecule as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 and an expression control sequence operatively linked to the nucleic acid molecule.

10 10. A transformant host cell including an expression vector comprising a nucleic acid molecule as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 and an expression control sequence operatively linked to the nucleic acid molecule.

15 11. A CLAX protein comprising the amino acid sequence as shown in SEQ ID NO:2.

12. A CLAX protein homologue comprising an amino acid sequence selected from the group consisting of the amino acid sequences as shown in SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8.

20 13. A method of producing CLAX protein, or a homologue thereof, said method comprising the steps of:

- a) inserting a nucleic acid sequence according to claim 1, 2, 3, 4, 5, 6, 7 or 8 encoding said CLAX protein, or a homologue thereof, into an appropriate expression vector,
- 25 b) transfecting said expression vector into an appropriate transfection host cell,
- c) growing said transfected host cells in an appropriate culture media, and
- d) purifying the CLAX protein, or a homologue thereof, from said
- 30 culture media.

14. An isolated nucleic acid sequence which hybridizes under stringent conditions to the nucleic acid sequence of claim 2, 4, 6 or 8, wherein said nucleic acid sequence contains at least 15 contiguous nucleic acids from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:9.

5

15. An antibody specific for CLAX protein as claimed in claim 11.

16. The antibody of claim 15 wherein said antibody is a monoclonal antibody.

10

17. An antibody specific for a CLAX protein homologue as claimed in claim 12.

18. The antibody of claim 17 wherein said antibody is a monoclonal antibody.

15

19. The CLAX protein of claim 11, produced by:

a) inserting a nucleic acid sequence encoding said CLAX protein into an appropriate expression vector,

20 b) transfecting said expression vector into an appropriate transfection host cell,

c) growing said transfected host cells in an appropriate culture media, and

25 d) purifying the tumor necrosis factor receptor from said culture media.

20. The CLAX protein homologue of claim 12, produced by:
- a) inserting a nucleic acid sequence encoding said CLAX protein homologue into an appropriate expression vector,
 - b) transfecting said expression vector into an appropriate
5 transfection host cell,
 - c) growing said transfected host cells in an appropriate culture media, and
 - d) purifying the tumor necrosis factor receptor from said culture media.
- 10
21. A method for identifying a ligand which is capable of binding to the CLAX protein of claim 11, or to a part of said CLAX protein, said method comprising the steps of:
- (a) reacting said CLAX protein, or part of said CLAX protein, with said
15 ligand which potentially is capable of binding to the CLAX protein or part of said CLAX protein, under conditions which permit the formation of ligand-CLAX protein complexes; and
 - (b) assaying for ligand-CLAX protein complexes, for free ligand, for non-complexed CLAX protein, or for activation of the CLAX protein.
- 20
22. A method for identifying a ligand which is capable of binding to the CLAX protein homologue of claim 12, or to a part of said CLAX protein homologue, said method comprising the steps of:
- (a) reacting said CLAX protein homologue, or part of said CLAX protein
25 homologue, with said ligand which potentially is capable of binding to the CLAX protein homologue or part of said CLAX protein homologue, under conditions which permit the formation of ligand-CLAX protein homologue complexes; and
 - (b) assaying for ligand-CLAX protein homologue complexes, for free
30 ligand, for non-complexed CLAX protein homologue, or for activation of the CLAX protein homologue.

23. A fusion protein comprising all or a portion of the CLAX protein as shown in SEQ ID NO:2, attached to a second polypeptide.

24. The fusion protein of claim 23 comprising the extracellular portion of the CLAX protein as shown in SEQ ID NO:2 attached to all or a portion of the hinge and/or constant region of a human IgG molecule.

25. A fusion protein comprising all or a portion of CLAX protein homologue as shown in SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, attached to a second polypeptide.

26. The fusion protein of claim 25 comprising the extracellular portion of the CLAX protein homologue as shown in SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, attached to all or a portion of the hinge and/or constant region of a human IgG molecule.

Schematic representation of contig assembly




FIG. 1

2/10

Human CLAX

GCAAA ATG CAT GAC AGT AAC AAT GTG GAG AAA GAC ATT ACA 41
 M H D S N N V E K D I T
 CCA TCT GAA TTG CCT GCA AAC CCA GGT TGT CTG CAT TCA AAA 83
 P S E L P A N P G C L H S K
 GAG CAT TCT ATT AAA GCT ACC TTA ATT TGG CGC TTA TTT TTC 125
 E H S I K A T L I W R L F F
 TTA ATC ATG TTT CTG ACA ATC ATA GTG TGT GGA ATG GTT GCT 167
 L I M F L T I I V C G M V A
 GCT TTA AGC GCA ATA AGA GCT AAC TGC CAT CAA GAG CCA TCA 209
 A L S A I R A N C H Q E P S
 GTA TGT CTT CAA GCT GCA TGC CCA GAA AGC TGG ATT GGT TTT 251
 V C L Q A A C P E S W I G F
 CAA AGA AAG TGT TTC TAT TTT TCT GAT GAC ACC AAG AAC TGG 293
 Q R K C F Y F S D D T K N W
 ACA TCA AGT CAG AGG TTT TGT GAC TCA CAA GAT GCT GAT CTT 335
 T S S Q R F C D S Q D A D L
 GCT CAG GTT GAA AGC TTC CAG GAA CTG AAT TTC CTG TTG AGA 377
 A Q V E S F Q E L N F L L R
 TAT AAA GGC CCA TCT GAT CAC TGG ATT GGG CTG AGC AGA GAA 419
 Y K G P S D H W I G L S R E
 CAA GGC CAA CCA TGG AAA TGG ATA AAT GGT ACT GAA TGG ACA 461
 Q G Q P W K W I N G T E W T
 AGA CAG TTA GTC ATG AAA GAA GAT GGT GCC AAC TTG TAT GTT 503
 R Q L V M K E D G A N L Y V
 GCA AAG GTT TCA CAA GTT CCT CGA ATG AAT CCA AGA CCT GTC 545
 A K V S Q V P R M N P R P V
 ATG GTT TCC TAT CCT GGG AGC AGG AGA GTG TGC CTA TTT GAA 587
 M V S Y P G S R R V C L F E
 TGA CAAAGGTGCC AGTAGTGCCA GGCCTACAC AGAGAGGAAG 630
 *
 TGGATTGTGTT CCAAATCAGA TATACATGTC TAGATGTTAC AGCAAAGCCC 680
 CAACTAATCT TTAGAAGCAT ATTGGAACCTG ATAACCTCCAT TTTAAAATGA 730
 GCAAAGAATT TATTTCTTAT ACCAACAGGT ATATGAAAAT ATGCTCAATA 780
 TCACTAATAA CTGGGAAAAT ACAATCAAAA TCATAGTAAA ATATTACCTG 830
 TTTTCATGGT GCTAATATTA CCTGTTCTCC CACTGCTAAT GACATACCCG 880
 AGACTGAGTA ATTTATAAAT AAAAGAGATT TAATTGAAAA AAAAAAAAAA 930
 A 931

FIG. 2A

3/10

CLAX clone7B

TGT	CTG	CAT	TCA	AAA	GAG	CAT	TCT	ATT	AAA	GCT	ACC	TTA	ATT	42
C	L	H	S	K	E	H	S	I	K	A	T	L	I	
TGG	CGC	TTA	TTT	TTC	TTA	ATC	ATG	TTT	CTG	ACA	ATC	ATA	GTG	84
W	R	L	F	F	L	I	M	F	L	T	I	I	V	
TGT	GGA	ATG	GTT	GCT	GCT	TTA	AGC	GCA	ATA	AGA	GCT	AAC	TGC	126
C	G	M	V	A	A	L	S	A	I	R	A	N	C	
CAT	CAA	GAG	CCA	TCA	GTA	TGT	CTT	CAA	GCT	GCA	TGC	CCA	GAA	168
H	Q	E	P	S	V	C	L	Q	A	A	C	P	E	
AGC	TGG	ATT	GGT	TTT	CAA	AGA	AAG	TGT	TTC	TAT	TTT	TCT	GAT	210
S	W	I	G	F	Q	R	K	C	F	Y	F	S	D	
GAC	ACC	AAG	AAC	TGG	ACA	TCA	AGT	CAG	AGG	TTT	TGT	GAC	TCA	252
D	T	K	N	W	T	S	S	Q	R	F	C	D	S	
CAA	GAT	GCT	GAT	CTT	GCT	CAG	GTT	GAA	AGC	TTC	CAG	GAA	CTG	294
Q	D	A	D	L	A	Q	V	E	S	F	Q	E	L	
AAT	TTC	CTG	TTG	AGA	TAT	AAA	GGC	CCA	TCT	GAT	CAC	TGG	ATT	336
N	F	L	L	R	Y	K	G	P	S	D	H	W	I	
GGG	CTG	AGC	AGA	GAA	CAA	GGC	CAA	CCA	TGG	AAA	TGG	ATA	AAT	378
G	L	S	R	E	Q	G	Q	P	W	K	W	I	N	
GGT	ACT	GAA	TGG	ACA	AGA	CAG	TTA	GTC	ATG	AAA	GAA	GAT	GGT	420
G	T	E	W	T	R	Q	L	V	M	K	E	D	G	
GCC	AAC	TTG	TAT	GTT	GCA	AAG	GTT	TCA	CAA	GTT	CCT	CGA	ATG	462
A	N	L	Y	V	A	K	V	S	Q	V	P	R	M	
AAT	CCA	AGA	CCT	GTC	ATG	GTT	TCC	TAT	CCT	GGG	AGC	AGG	AGA	504
N	P	R	P	V	M	V	S	Y	P	G	S	R	R	
GTG	TGC	CTA	TTT	GAA	TGA	CAA	AGG	TGC	CAG	TAG	TGC	CAG	GCA	546
V	C	L	F	E	*	Q	R	C	Q	*	C	Q	A	
CTA	CAC	AGA	GAG	GAA	GTG	GAT	TTG	TTC	CAA	ATC	AGA	TAT	ACA	588
L	H	R	E	E	V	D	L	F	Q	I	R	Y	T	
TGT	CTA	GAT	GTT	ACA	GCA	AAG	CCC	CAA	CTA	ATC	TTT	AGA	AGC	630
C	L	D	V	T	A	K	P	Q	L	I	F	R	S	
ATA	TTG	GAA	CTG	ATA	ACT	CCA	TTT	TAA	AAT	GAG	CAA	AGA	ATT	672
I	L	E	L	I	T	P	F	*	N	E	Q	R	I	
TAT	TTC	TTA	TAC	CAA	CAG	GTA	TAT	GAA	AAT	ATG	CTC	AAT	ATC	714
Y	F	L	Y	Q	Q	V	Y	E	N	M	L	N	I	

FIG. 2B-1

4/10

ACT	AAT	AAC	TGG	GAA	AAT	ACA	AAT	CAA	AAT	CAT	AGT	AAA	ATA	756
T	N	N	W	E	N	T	N	Q	N	H	S	K	I	
TTA	CCT	GTT	TTC	ATG	GTG	CTA	ATA	TTA	CCT	GTT	CTC	CCA	CTG	798
L	P	V	F	M	V	L	I	L	P	V	L	P	L	
CTA	ATG	ACA	TAC	CCG	AGA	CTG	AGT	AAT	TTA	TAA	ATA	AAA	GAG	840
L	M	T	Y	P	R	L	S	N	L	*	I	K	E	
ATT	TAA	TTG	AAA	AAA	AAA	AAA	AAA							864
I	*	L	K	K	K	K	K							

FIG. 2B-2

5/10

CLAX clone 2I

GC AAA ATG CAT GAC AGT AAC AAT GTG GAG AAA GAC ATT ACA 41
 K M H D S N N V E K D I T

CCA TCT GAA TTG CCT GCA AAC CCA GGT TGT CTG CAT TCA AAA 83
 P S E L P A N P G C L H S K

GAG CAT TCT ATT AAA GCT ACC TTA ATT TGG CGC TTA TTT TTC 125
 E H S I K A T L I W R L F F

TTA ATC ATG TTT CTG ACA ATC ATA GTG TGT GGA ATG GTT GCT 167
 L I M F L T I I V C G M V A

GCT TTA AGC GCA ATA AGA GCT AAC TGC CAT CAA GAG CCA TCA 209
 A L S A I R A N C H Q E P S

GTA TGT CTT CAA GCT GCA TGC CCA GAA AGC TGG ATT GGT TTT 251
 V C L Q A A C P E S W I G F

CAA AGA AAG TGT TTC TAT TTT TCT GAT GAC ACC AAG AAC TGG 293
 Q R K C F Y F S D D T K N W

ACA TCA AGT CAG AGG TTT TGT GAC TCA CAA GAT GCT GAT CTT 335
 T S S Q R F C D S Q D A D L

GCT CAG GTT GAA AGC TTC CAG GAA CTG AAT TTC CTG TTG AGA 377
 A Q V E S F Q E L N F L L R

TAT AAA GGC CCA TCT GAT CAC TGG ATT GGG CTG AGC AGA GAA 419
 Y K G P S D H W I G L S R E

CAA GGC CAA CCA TGG AAA TGG ATA AAT GGT ACT GAA TGG ACA 461
 Q G Q P W K W I N G T E W T

AGA CAG TTT CCT ATC CTG GGA GCA GGA GAG TGT GCC TAT TTG 503
 R Q F P I L G A G E C A Y L

AAT GAC AAA GGT GCC AGT AGT GCC AGG CAC TAC ACA GAG AGG 545
 N D K G A S S A R H Y T E R

AAG TGG ATT TGT TCC AAA TCA GAT ATA CAT GTC TAG ATG TTA 587
 K W I C S K S D I H V * M L

CAG CAA AGC CCC AAC TAA TCT TTA GAA GCA TAT TGG AAC TGA 629
 Q Q S P N * S L E A Y W N *

TAA CTC CAT TTT AAA ATG AGC AAA GAA TTT ATT TCT TAT ACC 671
 * L H F K M S K E F I S Y T

AAC AGG TAT ATG AAA ATA TGC TCA ATA TCA CTA ATA ACT GGG 713
 N R Y M K I C S I S L I T G

FIG. 2C-1

6/10

AAA	ATA	CAA	ATC	AAA	ATC	ATA	GTA	AAA	TAT	TAC	CTG	TTT	TCA	755
K	I	Q	I	K	I	I	V	K	Y	Y	L	F	S	
TGG	GGC	TAA	TAT	TAC	CTG	TTC	TCC	CAC	TGC	TAA	TGA	CAT	ACC	797
W	G	*	Y	Y	L	F	S	H	C	*	*	H	T	
CGA	GAC	TGA	GTA	ATT	TAT	AAA	TAA	AA						823
R	D	*	V	I	Y	K	*							

FIG. 2C-2

CLAX clone4A

GAG	CAT	TCT	ATT	AAA	GCT	ACC	TTA	ATT	TGG	CGC	TTA	TTT	TTC	42
E	H	S	I	K	A	T	L	I	W	R	L	F	F	
TTA	ATC	ATG	TTT	CTG	ACA	ATC	ATA	GTG	TGT	GGA	ATG	GTT	GCT	84
L	I	M	F	L	T	I	I	V	C	G	M	V	A	
GCT	TTA	AGC	GCA	ATA	AGA	GCT	AAC	TGC	CAT	CAA	GAG	CCA	TCA	126
A	L	S	A	I	R	A	N	C	H	Q	E	P	S	
GTA	TGT	CTT	CAA	GCT	GCA	TGC	CCA	GAA	AGC	TGG	ATT	GGT	TTT	168
V	C	L	Q	A	A	C	P	E	S	W	I	G	F	
CAA	AGA	AAG	TGT	TTC	TAT	TTT	TCT	GAT	GAC	ACC	AAG	AAC	TGG	210
Q	R	K	C	F	Y	F	S	D	D	T	K	N	W	
ACA	TCA	AGT	CAG	AGG	TTT	TGT	GAC	TCA	CAA	GAT	GCT	GAT	CTT	252
T	S	S	Q	R	F	C	D	S	Q	D	A	D	L	
GCT	CAG	GTT	GAA	AGC	TTC	CAG	GAA	CTG	GTT	TCC	TAT	CCT	GGG	294
A	Q	V	E	S	F	Q	E	L	V	S	Y	P	G	
AGC	AGG	AGA	GTG	TGC	CTA	TTT	GAA	TGA	CAA	AGG	TGC	CAG	TAG	336
S	R	R	V	C	L	F	E	*	Q	R	C	Q	*	
TGC	CAG	GCA	CTA	CAC	AGA	GAG	GAA	GTG	GAT	TTG	TTC	CAA	ATC	378
C	Q	A	L	H	R	E	E	V	D	L	F	Q	I	
AGA	TAT	ACA	TG											389
R	Y	T												

FIG. 2D

7/10

Human CLAX (7B) AND ITS VARIANTS (2I, AND 4A)

7B		CLHSKEHS	IKATLIWRLE	FLIMELTIIV
2I	MHDSNNVEK	DITPSELPAN	PGCLHSKEHS	IKATLIWRLE FLIMELTIIV
4A			EHS	IKATLIWRLE FLIMELTIIV
7B	CGMVAALSAI	RANCHQEPSV	CLQAACPESW	IGFQRKCFYF SDDTKNWTSS
2I	CGMVAALSAI	RANCHQEPSV	CLQAACPESW	IGFQRKCFYF SDDTKNWTSS
4A	CGMVAALSAI	RANCHQEPSV	CLQAACPESW	IGFQRKCFYF SDDTKNWTSS
7B	QRFCDSQDAD	LAQVESFQEL	NFLRLRYKGPS	DHWIGLSREQ GQPWKWINGT
2I	QRFCDSQDAD	LAQVESFQEL	NFLRLRYKGPS	DHWIGLSREQ GQPWKWINGT
4A	QRFCDSQDAD	LAQVESFQEL	VSYPGSRRCV	LFE*
7B	EWTRQLVMKE	DGANLYVAKV	SQVPRMNPRP	VMVSYPGSRRCV LFE*
2I	EWTRQFPILG	AGECAYLNDK	GASSARHYTE	RKWICKSKSDI HV*
4A				

FIG. 3A**Amino acid sequence alignment of the C-type lectin family**

hCLAX-7B	73	AACPESWIG	FQRKCFYFSD	DTKNWTSSQR	FCDSQDADLA
hCLAX-2I	73	AACPESWIG	FQRKCFYFSD	DTKNWTSSQR	FCDSQDADLA
hCLAX-4A	73	AACPESWIG	FQRKCFYFSD	DTKNWTSSQR	FCDSQDADLA
hCD69	83	SSCEDWVG	YQRKCYFIST	VKRSWTSAN	ACSEHGATLA
chk17.5	584	HVCPNAWVG	FQGKCYFSD	TESDWNSSRE	HCHRLGASLA
hAICL	33	SLCPYDWIG	FQNKCYFISK	EEGDWNSSKY	NCSTQHADLT
hASGPR	156	TCCPVNWVE	HQGSQYWFH	SGKAWAEAEK	YCQLENALHV
hCD94	59	CSCQEKWVG	YRCNCFYFIS	EQKTWNESRH	LCASQKSSLL
hMAFA	73	PSCPDRWMK	YGNHCYFYSV	EEKDWNSSLE	FCLARDSHLL
hCD23	161	NTCPEKWIN	FQRKCYFYGK	GTKQWVHARY	ACDDMEGQLV
		*	*	*	*

QVESFQELNF	LLRYKGPSDH	WIGLSREQGQ	P.WKWINGTE	150
QVESFQELNF	LLRYKGPSDH	WIGLSREQGQ	P.WKWINGTE	150
QVESFQEL				119

VIDSEKDMNF	LKRYAGREEH	WVGLKKEPGH	P.WKWSNGKE	160
TLDTKHEMEF	MLQYQRPADR	WIGLHRAEGD	EHWTWADGSA	663
IIDNIEEMNF	LRRYKCSSDH	WIGLKMAKNR	T.GQWVHGAT	110
VINSWEEQKF	IVQHTNPFT	WIGLTDSD..	GSWKWVDGTD	232
QLQNTDELDF	MS..SSQQFY	WIGLSYSEEH	TAWLWENGSA	135
VITDNQEMSL	LQVFLSEAF	WIGL...RNN	SGWRWEDGSP	148
SIHSPPEQDF	LTKHASHTGS	WIGLRNLDLK	GEFIWVDGSH	239
		* **	* *	

FIG. 3B

8/10

FUSION PROTEINS OF HUMAN CLAX (18) AND ITS VARIANTS (5, AND 13)

18	MASPLTRFLS	LNLLLLLGESI	ILGSGEAKPQ	APELRIFPKK	MDAELGQKVD
5	MASPLTRFLS	LNLLLLLGESI	ILGSGEAKPQ	APELRIFPKK	MDAELGQKVD
13	MASPLTRFLS	LNLLLLLGESI	ILGSGEAKPQ	APELRIFPKK	MDAELGQKVD
18	LVCEVLGSVS	QGCSWLFQNS	SSKLPQPTFV	YMASSHNKIT	WDEKLNSSKL
5	LVCEVLGSVS	QGCSWLFQNS	SSKLPQPTFV	YMASSHNKIT	WDEKLNSSKL
13	LVCEVLGSVS	QGCSWLFQNS	SSKLPQPTFV	YMASSHNKIT	WDEKLNSSKL
18	FSAMRDTNNK	YVLTILNKFSK	ENEGYYFCSV	ISNSVMYFSS	VVPVLQKVNS
5	FSAMRDTNNK	YVLTILNKFSK	ENEGYYFCSV	ISNSVMYFSS	VVPVLQKVNS
13	FSAMRDTNNK	YVLTILNKFSK	ENEGYYFCSV	ISNSVMYFSS	VVPVLQKVNS
18	TTTKPVL RTP	SPVHPTGTSQ	PQRPEDCRPR	GSVKGTGLDF	ACDPDPRANC
5	TTTKPVL RTP	SPVHPTGTSQ	PQRPEDCRPR	GSVKGTGLDF	ACDPDPRANC
13	TTTKPVL RTP	SPVHPTGTSQ	PQRPEDCRPR	GSVKGTGLDF	ACDPDPRANC
18	HQEPSVCLQA	ACPESWIGFQ	RKCFYFSDDT	KNWTSSQRFC	DSQDADLAQV
5	HQEPSVCLQA	ACPESWIGFQ	RKCFYFSDDT	KNWTSSQRFC	DSQDADLAQV
13	HQEPSVCLQA	ACPESWIGFQ	RKCFYFSDDT	KNWTSSQRFC	DSQDADLAQV
18	ESFQELN FLL	RYKGPSDHWI	GLSREQGQPW	KWINGTEWTR	QLVMKEDGAN
5	ESFQELN FLL	RYKGPSDHWI	GLSREQGQPW	KWINGTEWTR	QEPILGAGEC
13	ESFQELVSY P	GSRRVCLF E*			
18	LYVAKVSQVP	RMNPRPVMVS	YPGSRRVCLF	E*	
5	AYLNDKGASS	ARHYTERKWI	CSKSDIHV*		
13					

FIG. 4

9/10

CLAX gene expression in different tissues




FIG. 5B

FIG. 5A

10/10

Transcription kinetics of CLAX gene during T lymphocyte activation




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07404

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 14/435, 14/47; C12N 5/10, 15/12, 15/62, 15/63, 15/64

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 325, 471, 320.1, 252.3, 254.11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, CAS ONLINE, MEDLINE, CAPLUS

search terms: CLAX protein, DNA, polynucleotide, recombinant production.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/40151 A2 (GENETICS INSTITUTE, INC.) 30 October 1997 (30/10/1997), see entire document.	1-14, 19-20, 23-26



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 JUNE 2000

Date of mailing of the international search report

15 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 325, 471, 320.1, 252.3, 254.11

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-14, 19-20, 23-26, drawn to a nucleic acid encoding a CLAX protein, a vector, a host cell, a CLAX protein, a method of producing a CLAX protein, and a fusion protein comprising the CLAX protein.

Group II, claims 15-18, drawn to an antibody to the CLAX protein.

Group III, claims 21-22, drawn to a method for identifying a ligand which binds to the CLAX protein.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid encoding a CLAX protein, a vector, a host cell, a CLAX protein, a method of producing a CLAX protein, and a fusion protein comprising the CLAX protein. Further pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**